The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) address all aspects of
management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the …

Primary liver cancer is the second leading cause of cancer-related death worldwide and
therefore a major public health challenge. We review hypotheses of the cell of origin of liver …

Background In the ongoing phase I PROFILE 1001 study, crizotinib showed antitumor
activity in patients with ROS1-rearranged advanced non-small-cell lung cancer (NSCLC) …

Advanced, anaplastic lymphoma kinase (ALK)–positive lung cancer is currently treated with
the first-generation ALK inhibitor crizotinib followed by more potent, second-generation ALK …

Background Despite recent advances in the treatment of advanced non-small-cell lung
cancer, there remains a need for effective treatments for progressive disease. We assessed …

Advances in biomarkers, targeted therapies, and immuno-oncology have transformed the
clinical management of patients with advanced NSCLC. For oncogene-driven tumors, there …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

1. In KEYNOTE-189, patients with metastatic non-squamous NSCLC, PS 0-1, without
sensitising EGFR or ALK mutations, were randomised to receive pemetrexed and a platinum …

Purpose Provide evidence-based recommendations updating the 2015 ASCO guideline on
systemic therapy for patients with stage IV non–small-cell lung cancer (NSCLC). Methods …

Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene (ALK)–
rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience …